Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NYSE | USD | Real-time | ||
| BATS Europe | CHF | Delayed | ||
| BATS Europe | EUR | Delayed | ||
| OTC Markets | USD | Delayed | ||
| London | CHF | Real-time | ||
| Mexico | MXN | Delayed | ||
| Milan | EUR | Real-time | ||
| Switzerland | CHF | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Moscow | RUB | Real-time |
Novartis AG (NYSE: NVS) announced new data from the completed two-copy cohort of Phase 3 SPR1NT trial of Zolgensma (onasemnogene abeparvovec), gene therapy for spinal muscular...
Artios' small molecule Polθ inhibitor elicits BRCA-gene synthetic lethality and PARP inhibitor synergyGenetic screening reveals biomarkers within the PARP inhibitor resistance...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Sell | Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Buy | Strong Buy |
| Summary | Strong Sell | Strong Sell | Strong Sell | Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,450.90 | 2,459.50 | 2,446.10 | +8.4 | +0.34% | 613.21K | NASDAQ | |||
| 342.82 | 344.89 | 341.83 | +2.23 | +0.65% | 9.28M | NASDAQ | |||
| 56.88 | 58.76 | 55.66 | -1.42 | -2.44% | 74.33M | NYSE | |||
| 15.79 | 15.98 | 15.72 | +0.05 | +0.32% | 2.29M | NYSE | |||
| 68.05 | 68.73 | 66.75 | +1.56 | +2.35% | 14.85M | NYSE | |||
| 18.20 | 18.68 | 17.72 | +0.59 | +3.35% | 18.70M | NASDAQ | |||
| 76.10 | 77.97 | 66.10 | +10.71 | +16.38% | 32.88M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 3.02 | 3.27 | 2.65 | +0.540 | +21.77% | 30.39M | NYSE | |||
| 45.54 | 46.59 | 45.24 | +0.13 | +0.29% | 34.71M | NYSE | |||
| 28.74 | 28.84 | 28.61 | +0.09 | +0.31% | 27.56M | NYSE | |||
| 13.85 | 15.09 | 13.52 | +0.02 | +0.14% | 95.62M | NASDAQ | |||
| 217.84 | 219.58 | 215.56 | +2.98 | +1.39% | 9.20M | NYSE | |||
| 24.85 | 24.93 | 24.61 | +0.15 | +0.61% | 2.46M | NYSE | |||
| 24.41 | 26.52 | 17.00 | +4.32 | +21.50% | 28.18M | NASDAQ |
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; and collaboration with Artios Pharma Limited to create next generation DDR cancer therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
